ReNeuron Group plc (AIM: RENE), a UK-based stem cell leader in stem cell derived exosome technologies, announces that its Annual Report and Accounts for the year ended 31 March 2022 and the Notice of the 2022 Annual General Meeting (“AGM”) have today been sent to shareholders and are also available on the Company’s website.